Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001195 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT01001195: Completed Phase 2 study, sponsored by Allergan.
NCT01001195 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 165 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01001195, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
Primary Outcome
IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes is used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening).
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG AGN-210669 ophthalmic solution, 0.1%
- DRUG AGN-210669 ophthalmic solution, 0.075%
- DRUG AGN-210669 ophthalmic solution, 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT01001195 record still lists
NCT01001195 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 4 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT01001195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01001195 about?
NCT01001195 is a clinical study titled "Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution". This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
What is the current status of trial NCT01001195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2009-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01001195?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), AGN-210669 ophthalmic solution, 0.1% (DRUG), AGN-210669 ophthalmic solution, 0.075% (DRUG), AGN-210669 ophthalmic solution, 0.05% (DRUG).
Who is sponsoring clinical trial NCT01001195?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01001195's enrollment target sits among peer trials
165 410th of 2000 higher than 1,588 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia